OS from start of targeted therapy by selected characteristics
| OS . | Pts, n . | Events, n (%) . | Median, mo . | 12-mo survival, % . | 24-mo survival, % . | 36-mo survival, % . | 48-mo survival, % . |
|---|---|---|---|---|---|---|---|
| All patients | 991 | ||||||
| CLL-IPI risk group | |||||||
| Low | 133 | 1 (0.8) | Not reached | 100.0 | 100.0 | 100.0 | 100.0 |
| Intermediate | 308 | 14 (4.5) | Not reached | 98.7 | 96.7 | 96.0 | 95.4 |
| High | 483 | 39 (8.1) | Not reached | 97.9 | 97.1 | 93.9 | 91.0 |
| Very high | 67 | 10 (14.9) | Not reached | 95.5 | 91.0 | 89.4 | 85.2 |
| Age, y | |||||||
| ≤65 | 559 | 22 (3.9) | Not reached | 98.7 | 98.0 | 96.9 | 96.0 |
| >65 | 432 | 42 (9.7) | Not reached | 97.7 | 95.6 | 92.6 | 89.7 |
| Binet stage | |||||||
| A | 241 | 10 (4.1) | Not reached | 98.3 | 97.5 | 97.0 | 95.1 |
| B | 374 | 21 (5.6) | Not reached | 98.4 | 96.8 | 95.5 | 93.8 |
| C | 376 | 33 (8.8) | Not reached | 98.1 | 96.8 | 93.5 | 91.1 |
| Serum β2-microglobulin, mg/L | |||||||
| ≤3.5 | 371 | 11 (3.0) | Not reached | 99.5 | 98.6 | 97.4 | 97.0 |
| >3.5 | 620 | 53 (8.5) | Not reached | 97.6 | 95.9 | 93.6 | 90.8 |
| IGHV status | |||||||
| Unmutated | 588 | 45 (7.7) | Not reached | 98.1 | 96.9 | 94.1 | 91.3 |
| Mutated | 400 | 19 (4.7) | Not reached | 98.5 | 97.0 | 96.4 | 95.8 |
| TP53 status | |||||||
| None | 916 | 54 (5.9) | Not reached | 98.5 | 97.4 | 95.4 | 93.7 |
| Deleted and/or mutated | 75 | 10 (13.3) | Not reached | 96.0 | 91.9 | 90.5 | 86.6 |
| OS . | Pts, n . | Events, n (%) . | Median, mo . | 12-mo survival, % . | 24-mo survival, % . | 36-mo survival, % . | 48-mo survival, % . |
|---|---|---|---|---|---|---|---|
| All patients | 991 | ||||||
| CLL-IPI risk group | |||||||
| Low | 133 | 1 (0.8) | Not reached | 100.0 | 100.0 | 100.0 | 100.0 |
| Intermediate | 308 | 14 (4.5) | Not reached | 98.7 | 96.7 | 96.0 | 95.4 |
| High | 483 | 39 (8.1) | Not reached | 97.9 | 97.1 | 93.9 | 91.0 |
| Very high | 67 | 10 (14.9) | Not reached | 95.5 | 91.0 | 89.4 | 85.2 |
| Age, y | |||||||
| ≤65 | 559 | 22 (3.9) | Not reached | 98.7 | 98.0 | 96.9 | 96.0 |
| >65 | 432 | 42 (9.7) | Not reached | 97.7 | 95.6 | 92.6 | 89.7 |
| Binet stage | |||||||
| A | 241 | 10 (4.1) | Not reached | 98.3 | 97.5 | 97.0 | 95.1 |
| B | 374 | 21 (5.6) | Not reached | 98.4 | 96.8 | 95.5 | 93.8 |
| C | 376 | 33 (8.8) | Not reached | 98.1 | 96.8 | 93.5 | 91.1 |
| Serum β2-microglobulin, mg/L | |||||||
| ≤3.5 | 371 | 11 (3.0) | Not reached | 99.5 | 98.6 | 97.4 | 97.0 |
| >3.5 | 620 | 53 (8.5) | Not reached | 97.6 | 95.9 | 93.6 | 90.8 |
| IGHV status | |||||||
| Unmutated | 588 | 45 (7.7) | Not reached | 98.1 | 96.9 | 94.1 | 91.3 |
| Mutated | 400 | 19 (4.7) | Not reached | 98.5 | 97.0 | 96.4 | 95.8 |
| TP53 status | |||||||
| None | 916 | 54 (5.9) | Not reached | 98.5 | 97.4 | 95.4 | 93.7 |
| Deleted and/or mutated | 75 | 10 (13.3) | Not reached | 96.0 | 91.9 | 90.5 | 86.6 |